Targets › OPRL1
2 programs from 2 companies in 3 trials: 2 Phase 2, 1 Phase 3; Psychiatry, Other; next expected readout Jan 2027.
G protein-coupled opioid receptor that functions as a receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. (UniProt, P41146)
Open in Phaseline: the race on OPRL1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Adneuris Therapeutics | Cebranopadol Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist | OPRL1, OPRK1, OPRD1, OPRM1 | Phase 3 | Pain; Chronic Pain | Jan 2027 |
| Mclean Hospital | Nociceptin Receptor Antagonist (BTRX-246040) Nociceptin receptor antagonist | OPRL1 | Phase 2 | Depressive Disorder, Major | Mar 2027 |
Depressive Disorder, Major (1) Pain (1) Chronic Pain (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.